PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 5716人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255015, encodeId=5dc9125501534, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=中国肺癌临床研究的趋势：免疫治疗不能只关注PD-1/PD-L1, objectType=article, longId=177131, objectId=a09a1e71319d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a09a1e71319d, replyNumber=0, likeNumber=75, createdTime=2019-08-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a09a1e71319d, moduleTitle=中国肺癌临床研究的趋势：免疫治疗不能只关注PD-1/PD-L1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a09a1e71319d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255014, encodeId=72241255014ab, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=68, createdTime=2019-08-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255013, encodeId=01731255013a2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=中国肺癌临床研究趋势：免疫治疗不能只关注PD-1/PD-L1, objectType=article, longId=176914, objectId=368d1e691464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=368d1e691464, replyNumber=0, likeNumber=75, createdTime=2019-08-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=368d1e691464, moduleTitle=中国肺癌临床研究趋势：免疫治疗不能只关注PD-1/PD-L1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=368d1e691464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255012, encodeId=08181255012c6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=优于进口药背后：国产PD-1/PD-L1临床开发攻略, objectType=article, longId=176454, objectId=3e451e64543d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e451e64543d, replyNumber=0, likeNumber=78, createdTime=2019-07-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e451e64543d, moduleTitle=优于进口药背后：国产PD-1/PD-L1临床开发攻略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e451e64543d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255011, encodeId=fc1212550111e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率, objectType=article, longId=176346, objectId=05651e634668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05651e634668, replyNumber=0, likeNumber=59, createdTime=2019-07-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05651e634668, moduleTitle=Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05651e634668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255010, encodeId=35f71255010d0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Respirology：阻塞性睡眠呼吸暂停患者的PD-L1水平的分析, objectType=article, longId=176090, objectId=dba31e6090bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dba31e6090bc, replyNumber=0, likeNumber=58, createdTime=2019-07-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dba31e6090bc, moduleTitle=Respirology：阻塞性睡眠呼吸暂停患者的PD-L1水平的分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dba31e6090bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255009, encodeId=2a33125500964, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, objectType=article, longId=175359, objectId=a0671e535994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0671e535994, replyNumber=0, likeNumber=73, createdTime=2019-07-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0671e535994, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0671e535994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255008, encodeId=d2c712550087f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=67, createdTime=2019-06-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255007, encodeId=ca0b125500ef0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BioNTech启动其双特异性抗体DuoBody-PD-L1x4-1BB的首次人体I / IIa期试验, objectType=article, longId=168717, objectId=5016168e17c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5016168e17c6, replyNumber=0, likeNumber=76, createdTime=2019-06-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5016168e17c6, moduleTitle=BioNTech启动其双特异性抗体DuoBody-PD-L1x4-1BB的首次人体I / IIa期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5016168e17c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255006, encodeId=6eea1255006de, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, objectType=article, longId=168267, objectId=22fc16826e29, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22fc16826e29, replyNumber=0, likeNumber=66, createdTime=2019-06-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22fc16826e29, moduleTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22fc16826e29)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255005, encodeId=fc88125500555, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%, objectType=article, longId=168262, objectId=258116826276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=258116826276, replyNumber=0, likeNumber=62, createdTime=2019-06-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=258116826276, moduleTitle=研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=258116826276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255004, encodeId=3632125500457, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=了解PD-1与PD-L1，助你更好读懂免疫治疗, objectType=article, longId=168156, objectId=26cc1681560e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26cc1681560e, replyNumber=0, likeNumber=0, createdTime=2019-06-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26cc1681560e, moduleTitle=了解PD-1与PD-L1，助你更好读懂免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26cc1681560e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255003, encodeId=141d12550034c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, objectType=article, longId=168072, objectId=0b361680e285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b361680e285, replyNumber=0, likeNumber=67, createdTime=2019-06-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b361680e285, moduleTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b361680e285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255002, encodeId=b8a3125500287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, objectType=article, longId=167595, objectId=5ad816e5956b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ad816e5956b, replyNumber=0, likeNumber=66, createdTime=2019-06-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ad816e5956b, moduleTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ad816e5956b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255001, encodeId=5f5112550011f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用, objectType=article, longId=167544, objectId=773f16e5442b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=773f16e5442b, replyNumber=0, likeNumber=87, createdTime=2019-06-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=773f16e5442b, moduleTitle=ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=773f16e5442b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255000, encodeId=e58212550009b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, objectType=article, longId=166726, objectId=d16c166e26ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16c166e26ac, replyNumber=0, likeNumber=69, createdTime=2019-05-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16c166e26ac, moduleTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16c166e26ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254999, encodeId=a9951254999c7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, objectType=article, longId=166173, objectId=9b091661e313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b091661e313, replyNumber=0, likeNumber=72, createdTime=2019-05-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b091661e313, moduleTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b091661e313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254998, encodeId=cd481254998cd, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, objectType=article, longId=165339, objectId=4a3216533980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3216533980, replyNumber=0, likeNumber=63, createdTime=2019-05-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3216533980, moduleTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3216533980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254997, encodeId=a50d125499e9d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, objectType=article, longId=164834, objectId=5f4516483459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4516483459, replyNumber=0, likeNumber=41, createdTime=2019-04-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4516483459, moduleTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4516483459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254996, encodeId=f1791254996cd, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：PD-1/PD-L1和p53缺失协同促进弥漫性大B细胞淋巴瘤进展, objectType=article, longId=164252, objectId=ced71642525f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced71642525f, replyNumber=0, likeNumber=63, createdTime=2019-04-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced71642525f, moduleTitle=Blood：PD-1/PD-L1和p53缺失协同促进弥漫性大B细胞淋巴瘤进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced71642525f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

中国肺癌临床研究的趋势：免疫治疗不能只关注PD-1/PD-L1

2019-08-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-08-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

中国肺癌临床研究趋势：免疫治疗不能只关注PD-1/PD-L1

2019-08-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

优于进口药背后：国产PD-1/PD-L1临床开发攻略

2019-07-31

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancer Cell亮点 | 洪明奇团队开发新方法提高PD-L1阳性检出率

2019-07-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Respirology：阻塞性睡眠呼吸暂停患者的PD-L1水平的分析

2019-07-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定

2019-07-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

BioNTech启动其双特异性抗体DuoBody-PD-L1x4-1BB的首次人体I / IIa期试验

2019-06-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

实体瘤患者PD-L1表达与TMB、MSI的相关性研究

2019-06-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%

2019-06-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

了解PD-1与PD-L1，助你更好读懂免疫治疗

2019-06-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效

2019-06-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制

2019-06-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用

2019-06-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤

2019-05-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌

2019-05-17

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌

2019-05-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性

2019-04-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：PD-1/PD-L1和p53缺失协同促进弥漫性大B细胞淋巴瘤进展

2019-04-15

科室
- - 订阅+
  - 更多科室
工具
服务